Evexomostat, a novel drug targeting aggressive variant prostate cancer (AVPC), offers new hope for patients with treatment-resistant forms of the disease. Supported by a $1.2 million grant, it aims to disrupt the metabolic pathways that drive tumor growth in these challenging cancers. Preclinical models show it can halt tumor progression and overcome resistance to hormone therapies, paving the way for upcoming pilot and Phase II trials. If successful, evexomostat could address the urgent unmet needs of men facing advanced prostate cancer, improving both survival and quality of life.
Preclinical: Evexomostat for aggressi... - Fight Prostate Ca...
Preclinical: Evexomostat for aggressive prostate cancer
Written by
Maxone73
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Preclinical, interesting and easy to implement: kaempferol shows promise in treating emotional stress-aggravated prostate cancer metastasis
Kaempferol, a key active ingredient in the traditional Chinese medicine formula Chaihu-Shugan-San...
Phase 1 recruiting: QXL138AM, for CD138 expressing tumors
Another one I almost missed...
CD138 is expressed in advanced and aggressive prostate cancers,...
The Role of HSD3B1 in Prostate Cancer Progression and Treatment
I don't think I was tested against this gene, so I think it could be important for me as well.
A...
Preclinical: Will bacteria save us?? A new amazing tool!
Researchers at UMass Amherst have developed BacID, a bacteria-based cancer therapy that uses...
Phase 3 trial: 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer
Doctors in Perth, Australia are leading a Phase 3 clinical trial called ProstACT GLOBAL, which is...
Related Posts
- Warming Up the Cold: A New Hope for Immunotherapy in Prostate Cancer
Prostate Cancer and Immunotherapy Breakout Session at the 2020 CRI Virtual Immunotherapy Patient Summit with introduction to my next post
“Ancient Virus” Therapy for Prostate Cancer Receives DOD Grant, Genetic Engineering & Biotechnology News (GEN), April 27, 2023
Blue Sky News - Prostate Cancer Foundation of Australia - April 2023- New Target for Neuro Endocrine Prostate Cancer and does your circadian rhythm matter??
